• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary: Molecular and immunological features of TREM1 and its emergence as a prognostic indicator in glioma.

作者信息

Xue Jihao, Luo Zhilin, Wang Tao, Yin Qijia, Chen Ligang

机构信息

Department of Neurosurgery, the Affliliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.

Department of Geriatric Medicine, The Affliliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.

出版信息

Front Immunol. 2025 Jun 17;16:1577773. doi: 10.3389/fimmu.2025.1577773. eCollection 2025.

DOI:10.3389/fimmu.2025.1577773
PMID:40599767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12209258/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9504/12209258/f7c33f92ed98/fimmu-16-1577773-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9504/12209258/f7c33f92ed98/fimmu-16-1577773-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9504/12209258/f7c33f92ed98/fimmu-16-1577773-g001.jpg

相似文献

1
Commentary: Molecular and immunological features of TREM1 and its emergence as a prognostic indicator in glioma.述评：触发受体表达分子1（TREM1）的分子和免疫学特征及其作为胶质瘤预后指标的出现
Front Immunol. 2025 Jun 17;16:1577773. doi: 10.3389/fimmu.2025.1577773. eCollection 2025.
2
Molecular and immunological features of TREM1 and its emergence as a prognostic indicator in glioma.TREM1 的分子和免疫学特征及其作为脑胶质瘤预后指标的出现。
Front Immunol. 2024 Feb 2;15:1324010. doi: 10.3389/fimmu.2024.1324010. eCollection 2024.
3
Development of a prognostic nomogram and risk factor analysis for survival in -positive non-cardia gastric adenocarcinoma patients.阳性非贲门胃腺癌患者生存的预后列线图开发及危险因素分析
Transl Cancer Res. 2025 May 30;14(5):2822-2834. doi: 10.21037/tcr-24-1776. Epub 2025 May 26.
4
Comprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk factor and its potential prognostic value in SKCM.全面的泛癌分析揭示NTN1作为一种免疫浸润风险因素及其在皮肤黑色素瘤中的潜在预后价值。
Sci Rep. 2025 Jan 25;15(1):3223. doi: 10.1038/s41598-025-85444-x.
5
Development and validation of a nomogram for predicting cancer-related fatigue in patients with glioma: a multicenter study.预测胶质瘤患者癌症相关疲劳的列线图的开发与验证：一项多中心研究
Front Oncol. 2025 Jun 16;15:1497151. doi: 10.3389/fonc.2025.1497151. eCollection 2025.
6
Construction and validation of a prognostic model for glioma: an analysis based on mismatch repair-related genes and their correlation with clinicopathological features.胶质瘤预后模型的构建与验证：基于错配修复相关基因及其与临床病理特征相关性的分析
Transl Cancer Res. 2025 May 30;14(5):2690-2706. doi: 10.21037/tcr-24-2045. Epub 2025 May 9.
7
Interrogation of macrophage-related prognostic signatures reveals a potential immune-mediated therapy strategy by histone deacetylase inhibition in glioma.对巨噬细胞相关预后特征的研究揭示了一种通过抑制组蛋白去乙酰化酶在胶质瘤中进行潜在免疫介导治疗的策略。
Front Oncol. 2025 Jun 6;15:1554845. doi: 10.3389/fonc.2025.1554845. eCollection 2025.
8
Single-cell and bulk transcriptome analysis unveils a ligand-receptor-based signature for prognostication and reveals that TREM1 controls the malignant behaviors of hepatocellular carcinoma.单细胞和批量转录组分析揭示了一种基于配体-受体的预后特征，并表明TREM1控制肝细胞癌的恶性行为。
Acta Biochim Biophys Sin (Shanghai). 2025 Jun 23. doi: 10.3724/abbs.2025059.
9
[Mechanisms of Neiyiting Decoction in Preventing Postoperative Recurrence of Endometriosis by Inhibiting Macrophage M1 Polarization Through the TREM1/TLR4/NF-κB Signaling Pathway].[内异停方通过TREM1/TLR4/NF-κB信号通路抑制巨噬细胞M1极化预防子宫内膜异位症术后复发的机制]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2025 Mar 20;56(2):371-381. doi: 10.12182/20250360601.
10
Development of a Radiomic-clinical Nomogram for Prediction of Survival in Patients with Nasal Extranodal Natural Killer/T-cell Lymphoma.用于预测鼻型结外自然杀伤/T细胞淋巴瘤患者生存情况的影像组学-临床列线图的开发
Curr Med Imaging. 2025 Jun 19. doi: 10.2174/0115734056319914250605053257.

本文引用的文献

1
Misuse of the Cox proportional hazards model and alternative approaches in kidney outcome research.Cox比例风险模型在肾脏结局研究中的误用及替代方法
Kidney Int. 2024 Dec;106(6):1186. doi: 10.1016/j.kint.2024.08.026.
2
Limitations of using COX proportional hazards model in cardiovascular research.COX 比例风险模型在心血管研究中的局限性。
Cardiovasc Diabetol. 2024 Jun 26;23(1):219. doi: 10.1186/s12933-024-02302-2.
3
Methods for non-proportional hazards in clinical trials: A systematic review.临床试验中非比例风险方法：系统评价。
Stat Methods Med Res. 2024 Jun;33(6):1069-1092. doi: 10.1177/09622802241242325. Epub 2024 Apr 9.
4
Molecular and immunological features of TREM1 and its emergence as a prognostic indicator in glioma.TREM1 的分子和免疫学特征及其作为脑胶质瘤预后指标的出现。
Front Immunol. 2024 Feb 2;15:1324010. doi: 10.3389/fimmu.2024.1324010. eCollection 2024.
5
Assessing Performance and Clinical Usefulness in Prediction Models With Survival Outcomes: Practical Guidance for Cox Proportional Hazards Models.评估生存结局预测模型的性能和临床实用性：Cox 比例风险模型的实用指南。
Ann Intern Med. 2023 Jan;176(1):105-114. doi: 10.7326/M22-0844. Epub 2022 Dec 27.
6
A flexible parametric accelerated failure time model and the extension to time-dependent acceleration factors.一种灵活的参数加速失效时间模型及其对时变加速因子的扩展。
Biostatistics. 2023 Jul 14;24(3):811-831. doi: 10.1093/biostatistics/kxac009.
7
Competing Risks, Treatment Switching, and Informative Censoring.竞争风险、治疗转换与信息删失
JAMA Cardiol. 2021 Aug 1;6(8):871-873. doi: 10.1001/jamacardio.2021.1239.
8
Why Test for Proportional Hazards?为什么要检验比例风险？
JAMA. 2020 Apr 14;323(14):1401-1402. doi: 10.1001/jama.2020.1267.
9
Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week.临床试验中事件时间终点的非比例风险：JACC 每周综述专题。
J Am Coll Cardiol. 2019 Oct 22;74(16):2102-2112. doi: 10.1016/j.jacc.2019.08.1034.
10
Limitations of hazard ratios in clinical trials.临床试验中风险比的局限性。
Eur Heart J. 2019 May 1;40(17):1378-1383. doi: 10.1093/eurheartj/ehy770.